The CD20-specific Engineered Toxin Antibody MT-3724 Exhibits Lethal Effects Against Mantle Cell Lymphoma

Overview

Journal Blood Cancer J

Date 2018 Mar 22

PMID 29559616

Citations 6

Authors

Shengjian Huang

Changying Jiang

Hui Zhang

Taylor Bell

Hui Guo

Yang Liu

Yixin Yao

Dongfeng Zeng

Makhdum Ahmed

Krystle Nomie

Leo Zhang

Michael Wang

Affiliations

Soon will be listed here.

Citing Articles

Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma.

Hamlin P, Musteata V, Park S, Burnett C, Dabovic K, Strack T Cancer Res Commun. 2023; 2(5):307-315.

PMID: 36875713 PMC: 9981212. DOI: 10.1158/2767-9764.CRC-22-0056.

Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma.

Lin C, Galal A, Rizzieri D, Chawla S, Lee S, Georgy A Cancer Invest. 2023; :1-10.

PMID: 36657101 PMC: 10387504. DOI: 10.1080/07357907.2022.2162073.

Bacteria-derived chimeric toxins as potential anticancer agents.

Khoshnood S, Fathizadeh H, Neamati F, Negahdari B, Baindara P, Abdullah M Front Oncol. 2022; 12:953678.

PMID: 36158673 PMC: 9491211. DOI: 10.3389/fonc.2022.953678.

Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861.

Panjideh H, Niesler N, Weng A, Fuchs H Toxins (Basel). 2022; 14(7).

PMID: 35878216 PMC: 9318199. DOI: 10.3390/toxins14070478.

Engineered antibody fusion proteins for targeted disease therapy.

Silver A, Leonard E, Gould J, Spangler J Trends Pharmacol Sci. 2021; 42(12):1064-1081.

PMID: 34706833 PMC: 8922469. DOI: 10.1016/j.tips.2021.09.009.

References

Pileri S, Ascani S, Sabattini E, Fraternali-Orcioni G, Poggi S, Piccioli M . The pathologist's view point. Part I--indolent lymphomas. Haematologica. 2000; 85(12):1291-307. View

Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J . ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202-8. DOI: 10.1038/nm.3048. View

Wang M, Rule S, Martin P, Goy A, Auer R, Kahl B . Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507-16. PMC: 4513941. DOI: 10.1056/NEJMoa1306220. View

Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P . Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014; 4(9):1022-35. PMC: 4155003. DOI: 10.1158/2159-8290.CD-14-0098. View

Allahyari H, Heidari S, Ghamgosha M, Saffarian P, Amani J . Immunotoxin: A new tool for cancer therapy. Tumour Biol. 2017; 39(2):1010428317692226. DOI: 10.1177/1010428317692226. View

Zhang S, Smith S, Zhang S, Wang Y . Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2015; 170(4):445-56. DOI: 10.1111/bjh.13427. View

Morschhauser F, Cartron G, Thieblemont C, Solal-Celigny P, Haioun C, Bouabdallah R . Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013; 31(23):2912-9. DOI: 10.1200/JCO.2012.46.9585. View

Jones N, Islur A, Haq R, Mascarenhas M, Karmali M, Perdue M . Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. Am J Physiol Gastrointest Liver Physiol. 2000; 278(5):G811-9. DOI: 10.1152/ajpgi.2000.278.5.G811. View

Jares P, Campo E . Advances in the understanding of mantle cell lymphoma. Br J Haematol. 2008; 142(2):149-65. DOI: 10.1111/j.1365-2141.2008.07124.x. View

10.

Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S . B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clin Cancer Res. 2017; 23(15):4212-4223. PMC: 5540787. DOI: 10.1158/1078-0432.CCR-16-2703. View

11.

Morschhauser F, Marlton P, Vitolo U, Linden O, Seymour J, Crump M . Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol. 2010; 21(9):1870-1876. DOI: 10.1093/annonc/mdq027. View

12.

Coiffier B, Radford J, Bosly A, Martinelli G, Verhoef G, Barca G . A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Haematol. 2013; 163(3):334-42. DOI: 10.1111/bjh.12537. View

13.

Erwert R, Eiting K, Tupper J, Winn R, Harlan J, Bannerman D . Shiga toxin induces decreased expression of the anti-apoptotic protein Mcl-1 concomitant with the onset of endothelial apoptosis. Microb Pathog. 2003; 35(2):87-93. DOI: 10.1016/s0882-4010(03)00100-1. View

14.

Morschhauser F, Leonard J, Fayad L, Coiffier B, Petillon M, Coleman M . Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009; 27(20):3346-53. DOI: 10.1200/JCO.2008.19.9117. View

15.

Smith W, Kane A, Campbell S, Acheson D, Cochran B, Thorpe C . Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. Infect Immun. 2003; 71(3):1497-504. PMC: 148871. DOI: 10.1128/IAI.71.3.1497-1504.2003. View